美股異動|再鼎醫藥盤前升超3% 績後獲多家大行上調目標價
再鼎醫藥(ZLAB.US)盤前升超3%,報32.7美元。消息面上,再鼎醫藥公佈2024年度財報,總收入同比增加49.6%至3.99億美元,主要是艾加莫德持續的強勁表現以及則樂和紐再樂銷售收入持續增長。該公司預計2025年全年總收入將介於5.60億至5.90億美元之間,到第四季度實現非美國公認會計准則經營利潤盈利。花旗將再鼎醫藥美股目標價由70美元輕微上調至71美元,給予“買入”評級,相信今年的渠道數據、Vygart增長、越來越接近2026年KarXT推出的前景,應能重新激發投資者對該股的情緒。高盛將再鼎醫藥H股目標價從40.4港元上調至42.01港元,給予“買入”評級,重申2025年是再鼎醫藥發展里程碑年。中金將再鼎醫藥H股目標價上調22.5%至34.41港元,維持“跑贏大市”評級,留意到公司在今明兩年有大量的催化劑。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.